Literature DB >> 32051558

First-line PARP inhibition in ovarian cancer - standard of care for all?

Susana N Banerjee1, Christopher J Lord2.   

Abstract

Entities:  

Year:  2020        PMID： 32051558     DOI： 10.1038/s41571-020-0335-9

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  7 in total

Review 1.  PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?

Authors:  Elisena Franzese; Anna Diana; Sara Centonze; Sandro Pignata; Ferdinando De Vita; Fortunato Ciardiello; Michele Orditura
Journal:  Front Oncol       Date:  2020-06-12       Impact factor: 6.244

Review 2.  Possible Role of Metformin as an Immune Modulator in the Tumor Microenvironment of Ovarian Cancer.

Authors:  Faye K Tsogas; Daniel Majerczyk; Peter C Hart
Journal:  Int J Mol Sci       Date:  2021-01-16       Impact factor: 5.923

3.  Emerging strategies for treating metastasis.

Authors:  Mark Esposito; Shridar Ganesan; Yibin Kang
Journal:  Nat Cancer       Date:  2021-03-24

4.  VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status.

Authors:  Francesca Bizzaro; Simon T Barry; Maria Rosa Bani; Raffaella Giavazzi; Ilaria Fuso Nerini; Molly A Taylor; Alessia Anastasia; Massimo Russo; Giovanna Damia; Federica Guffanti; Francesca Guana; Paola Ostano; Lucia Minoli; Maureen M Hattersley; Stephanie Arnold; Antonio Ramos-Montoya; Stuart C Williamson; Alessandro Galbiati; Jelena Urosevic; Elisabetta Leo; Ugo Cavallaro; Carmen Ghilardi
Journal:  J Hematol Oncol       Date:  2021-11-06       Impact factor: 17.388

Review 5.  Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system.

Authors:  Nirashaa T Bound; Cassandra J Vandenberg; Apriliana E R Kartikasari; Magdalena Plebanski; Clare L Scott
Journal:  Front Genet       Date:  2022-09-09       Impact factor: 4.772

6.  VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases.

Authors:  Arun Kanakkanthara; Larry M Karnitz; Thomas L Ekstrom; Nicholas M Pathoulas; Amelia M Huehls
Journal:  Mol Cancer Ther       Date:  2021-06-17       Impact factor: 6.261

7.  AKT Isoforms Interplay in High-Grade Serous Ovarian Cancer Prognosis and Characterization.

Authors:  Eros Azzalini; Domenico Tierno; Michele Bartoletti; Renzo Barbazza; Giorgio Giorda; Fabio Puglisi; Sabrina Chiara Cecere; Nunzia Simona Losito; Daniela Russo; Giorgio Stanta; Vincenzo Canzonieri; Serena Bonin
Journal:  Cancers (Basel)       Date:  2022-01-08       Impact factor: 6.639
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.